Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.
Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle CR, Wahlestedt C. Swords RT, et al. Among authors: watts jm. Leuk Res. 2018 Jan;64:34-41. doi: 10.1016/j.leukres.2017.11.008. Epub 2017 Nov 11. Leuk Res. 2018. PMID: 29175379 Free PMC article. Clinical Trial.
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. Swords RT, et al. Among authors: watts jm. Leuk Res. 2016 Nov;50:123-131. doi: 10.1016/j.leukres.2016.09.012. Epub 2016 Sep 28. Leuk Res. 2016. PMID: 27736729 Clinical Trial.
Acute leukemia in adult Hispanic Americans: a large-population study.
Swords R, Sznol J, Elias R, Watts J, Zelent A, Martin E, Vargas F, Bethel-Ellison S, Kobetz E. Swords R, et al. Blood Cancer J. 2016 Oct 14;6(10):e484. doi: 10.1038/bcj.2016.94. Blood Cancer J. 2016. PMID: 27740629 Free PMC article. No abstract available.
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
Swords RT, Watts J, Erba HP, Altman JK, Maris M, Anwer F, Hua Z, Stein H, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC, DeAngelo DJ. Swords RT, et al. Blood Cancer J. 2017 Feb 3;7(2):e520. doi: 10.1038/bcj.2017.1. Blood Cancer J. 2017. PMID: 28157218 Free PMC article. Clinical Trial. No abstract available.
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].
Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. Swords RT, et al. Among authors: watts jm. Leuk Res. 2017 Aug;59:65. doi: 10.1016/j.leukres.2017.02.007. Epub 2017 May 30. Leuk Res. 2017. PMID: 28575698 No abstract available.
191 results